MARK CHIU, PhD
Chief Scientific Officer
Dr. Mark Chiu is the President of R&D as well as Chief Scientific Officer at Tavotek Biotherapeutics. He has nearly 35 years of experience in new drug discovery for AbbVie/Abbott Laboratories and Janssen. Prior to joining Tavotek, Dr. Chiu was the Head of the Process Analytical Sciences at Biotherapeutics Development and Head of Antibody Engineering in the Biologics Research Department at Janssen, the pharmaceutical branch of Johnson & Johnson (J&J).
Dr. Chiu began his career as a synthetic organic chemist at Microgenics developing rapid and robust diagnostic assays that are now utilized by Roche Diagnostics. In AbbVie/Abbott Laboratories, he led an Advanced Technology Team preparing full length mammalian membrane proteins (GPCRs, ligand gated and voltage gated ion channels, and transporters) for structure-function drug discovery studies. At Janssen, he led the Developability Team as part of lead optimization, and later transitioned to Antibody Engineering where he guided the development of therapeutic bispecific and multispecific antibodies and fusion proteins for Oncology, Immunology, Neuroscience, Metabolic Diseases, and Chronic Infectious Diseases. His leadership resulted in more than 15 New Molecular Entities with 6 projects transitioning from Phase 1 to Phase 3 trials. He fostered defense of numerous patents critical to both composition of matter and process patents. He also led a team that was responsible for analytical testing to support early and late phase development.
Dr. Chiu received his B.S. in Biophysics from University of California at Berkeley. He obtained his Ph.D. degree from the University of Illinois at Urbana-Champaign, and then completed postdoctoral training at the Laboratory of Physical Chemistry at the Federal Institute of Technology at Zurich, Switzerland and the Department of Microbiology at the University of Basel Biocentre. Dr. Chiu had comprehensive training and extensive research experience in molecular and cell biology, biochemistry, biophysics, and biotechnology. He authored/co-authored over 20 patents and 100 publications in many prestigious journals, including research articles in Science and Nature. He has been members of grant review committees and is an editor for Current Protocols and Antibodies.